Yahoo
NasdaqGS - Delayed Quote USD

Xeris Biopharma Holdings, Inc. (XERS)

8.53 -0.06 (-0.70%)
At close: September 4 at 4:00:00 PM EDT
8.54 +0.01 (+0.12%)
After hours: September 4 at 7:30:02 PM EDT
Trade XERS on Coinbase
View in AlphaSpace Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
335,414
291,845
203,070
163,914
110,248
Cost of Revenue
45,029
42,569
36,832
28,645
22,634
Gross Profit
290,385
249,276
166,238
135,269
87,614
Operating Expense
253,792
224,380
199,884
179,279
169,554
Operating Income
36,593
24,896
-33,646
-44,010
-81,940
Net Non Operating Interest Income Expense
-22,976
-24,342
-25,164
-21,858
-11,524
Other Income Expense
--
--
1,706
2,364
-2,620
Pretax Income
-17,165
554
-57,104
-63,504
-96,084
Tax Provision
0
0
-2,268
-1,249
-1,424
Net Income Common Stockholders
-17,165
554
-54,836
-62,255
-94,660
Diluted NI Available to Com Stockholders
-17,165
554
-54,836
-62,255
-94,660
Basic EPS
-0.10
0.00
-0.37
-0.45
-0.70
Diluted EPS
-0.10
0.00
-0.37
-0.45
-0.70
Basic Average Shares
168,279.02
160,425.20
146,772.76
137,674.86
135,628.72
Diluted Average Shares
180,596.54
172,742.72
146,772.76
137,674.86
135,628.72
Total Operating Income as Reported
36,593
24,896
-33,646
-44,010
-81,940
Total Expenses
298,821
266,949
236,716
207,924
192,188
Net Income from Continuing & Discontinued Operation
-17,165
554
-54,836
-62,255
-94,660
Normalized Income
13,617
554
-56,474.24
-64,572.50
-92,078.83
Interest Income
5,276
4,742
5,321
4,751
2,578
Interest Expense
28,252
29,084
30,485
26,609
14,102
Net Interest Income
-22,976
-24,342
-25,164
-21,858
-11,524
EBIT
11,087
29,638
-26,619
-36,895
-81,982
EBITDA
23,893
42,331
-13,994
-23,735
-69,314
Reconciled Cost of Revenue
43,066
40,719
35,050
26,328
20,809
Reconciled Depreciation
12,806
12,693
12,625
13,160
12,668
Net Income from Continuing Operation Net Minority Interest
-17,165
554
-54,836
-62,255
-94,660
Total Unusual Items Excluding Goodwill
-30,782
0
1,706
2,364
-2,620
Total Unusual Items
-30,782
0
1,706
2,364
-2,620
Normalized EBITDA
54,675
42,331
-15,700
-26,099
-66,694
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
67.76
46.50
-38.83
12/31/2022 - 6/21/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: